Bristol-Myers Squibb Company (BMY) 76.58 $BMY
Bayer Expands Drug Discovery Collaboration with X-Chem
Zacks Equity Research - Zacks Investment Research - Wed Jul 13, 3:06PM CDT
Bayer (BAYRY) inked an expanded global drug discovery deal with X-Chem, Inc. across multiple therapeutic areas and target classes.
MACK: 5.36 (-0.33), FCSC: 1.17 (-0.02), BMY: 76.58 (+0.38)
Top 7 Research Reports for July 13, 2016
Sheraz Mian - Zacks Investment Research - Wed Jul 13, 12:00PM CDT
Top 7 Research Reports for July 13, 2016
SU: 28.23 (-0.30), EBAY: 25.12 (-0.01), COP: 42.87 (-0.93), BMY: 76.58 (+0.38), VIAB: 44.80 (-0.64), PEP: 109.91 (+1.12)
Watch for Shares of Bristol-Myers Squibb (BMY) to Approach Resistance at $77.15
Comtex SmarTrend(R) - Wed Jul 13, 8:35AM CDT
Shares of Bristol-Myers Squibb (NYSE:BMY) opened today above their pivot of $76.08 and have already reached the first level of resistance at $76.67. Analysts will be watching for a cross of the next upside pivot targets of $77.15 and $78.22.
BMY: 76.58 (+0.38)
After Yesterday's Rally of 1.31% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Tue Jul 12, 1:52PM CDT
Bristol-Myers Squibb (NYSE:BMY) traded in a range yesterday that spanned from a low of $75.48 to a high of $76.38. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $75.84 on volume of 2.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BMY: 76.58 (+0.38)
Technical Report on Drug Manufacturers - Major Stocks - Bristol-Myers Squibb, AstraZeneca, Eli Lilly, and GlaxoSmithKline
PR Newswire - Mon Jul 11, 6:55AM CDT
On Friday, July 08, 2016, the NASDAQ Composite ended the trading session at 4,956.76, up 1.64%; the Dow Jones Industrial Average advanced 1.40%, to finish at 18,146.74; and the S&P 500 closed at 2,129.90, up 1.53%. The gains were broad based as all the sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Bristol-Myers Squibb Company (NYSE: BMY), AstraZeneca PLC (NYSE: AZN), Eli Lilly and Company (NYSE: LLY), and GlaxoSmithKline PLC (NYSE: GSK). Learn more about these stocks by accessing their free notes at:
AZN: 30.16 (-0.04), LLY: 79.36 (-0.31), GSK: 43.75 (+0.03), BMY: 76.58 (+0.38)
Alnylam (ALNY) Begins Phase I/II Study on Chronic HBV Drug
Zacks Equity Research - Zacks Investment Research - Fri Jul 08, 10:34AM CDT
Alnylam Pharmaceuticals (ALNY) announced that it has started a phase I/II study on ALN-HBV for the treatment of chronic hepatitis B virus infection.
ALNY: 62.82 (-1.18), INVA: 11.89 (+0.13), PFE: 36.31 (+0.07), BMY: 76.58 (+0.38)
Bristol-Myers Buys Cormorant, Focus on Immuno-Oncology
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 9:02AM CDT
Bristol-Myers (BMY) acquires a privately held pharma company, Cormorant Pharmaceuticals, to bolster its immuno-oncology pipeline.
INVA: 11.89 (+0.13), PFE: 36.31 (+0.07), BMY: 76.58 (+0.38)
CSI Laboratories Launches PD-L1 Expression Assay That Can Be Used in Conjunction with Multiple Immunotherapies
BusinessWire - Thu Jul 07, 7:30AM CDT
CSI Laboratories, a private national reference laboratory specializing in cancer diagnostics, announced today the availability of a PD-L1 (programmed death-ligand 1) immunohistochemical (IHC) protein expression assay that can be used to potentially predict a patient's response to several commercially available PD-1/PD-L1 inhibitor therapies.(1)
MRK: 59.55 (-0.05), BMY: 76.58 (+0.38)
Amgen's Kyprolis Gains Approval in EU for Label Expansion
Zacks Equity Research - Zacks Investment Research - Wed Jul 06, 9:37AM CDT
Amgen's (AMGN) Kyprolis label has been expanded in the EU for the treatment of relapsed multiple myeloma patients.
AMGN: 160.52 (-1.44), ABBV: 64.77 (-0.73), BMY: 76.58 (+0.38), CELG: 101.76 (-1.65)
Bristol-Myers Squibb, Deutsche Bank, Alphabet, Blucora and Internap highlighted as Zacks Bull and Bear of the Day
Zacks Equity Research - Zacks Investment Research - Tue Jul 05, 8:30AM CDT
Bristol-Myers Squibb, Deutsche Bank, Alphabet, Blucora and Internap highlighted as Zacks Bull and Bear of the Day
DB: 13.95 (-0.15), GOOGL: 729.48 (-3.03), BMY: 76.58 (+0.38), INAP: 2.42 (+0.04), BCOR: 12.09 (+0.15)
Zacks.com featured highlights: Fresh Del Monte Produce, Post Holdings, Bristol-Myers Squibb, Southern National Bancorp of Virginia and Apple Hospitality REIT
Zacks Equity Research - Zacks Investment Research - Tue Jul 05, 8:30AM CDT
Zacks.com featured highlights: Fresh Del Monte Produce, Post Holdings, Bristol-Myers Squibb, Southern National Bancorp of Virginia and Apple Hospitality REIT
POST: 86.98 (+0.59), APLE: 19.70 (+0.14), FDP: 55.32 (+0.69), SONA: 12.37 (+0.02), BMY: 76.58 (+0.38)
Bristol-Myers Squibb Acquires Cormorant Pharmaceuticals
BusinessWire - Tue Jul 05, 5:59AM CDT
--Broadens Bristol-Myers Squibb's oncology pipeline focus on the tumor microenvironment and combination therapy
BMY: 76.58 (+0.38)
Bull of the Day: Bristol-Myers Squibb (BMY)
Neena Mishra - ZACKS - Tue Jul 05, 2:40AM CDT
Bull of the Day: Bristol-Myers Squibb (BMY)
BMY: 76.58 (+0.38)
XBiotech Xilonix Positive in Phase III Colorectal Cancer Study
Zacks Equity Research - Zacks Investment Research - Mon Jul 04, 8:06AM CDT
XBiotech (XBIT) announced positive results from a phase III study on Xilonix for the treatment of advanced colorectal cancer.
XBIT: 18.21 (-0.03), ANIP: 54.26 (-1.47), PFE: 36.31 (+0.07), BMY: 76.58 (+0.38)
Novartis' Systemic Mastocytosis Drug Positive in Phase II
Zacks Equity Research - Zacks Investment Research - Fri Jul 01, 3:43PM CDT
Novartis AG (NVS) announced that data from its phase II study, CPKC412D2201, on PKC412 (midostaurin) was published in The New England Journal of Medicine.
JNJ: 123.00 (+0.08), PFE: 36.31 (+0.07), BMY: 76.58 (+0.38), NVS: 82.03 (+0.35)
Shire Stock Up Despite Mixed Data on Pipeline Candidate
Zacks Equity Research - Zacks Investment Research - Fri Jul 01, 3:30PM CDT
Shire plc (SHPG) announced disappointing results from a phase II study on pipeline candidate SHP607.
JNJ: 123.00 (+0.08), SHPG: 192.49 (-2.82), PFE: 36.31 (+0.07), BMY: 76.58 (+0.38)
5 Low Beta Stocks to Withstand Market Volatility
Zacks Equity Research - Zacks Investment Research - Fri Jul 01, 8:46AM CDT
It will be wise if investors include low risk stocks in their portfolio. Such a portfolio could be created easily based on the low beta strategy which selects stocks less prone to risks than the market.
POST: 86.98 (+0.59), APLE: 19.70 (+0.14), FDP: 55.32 (+0.69), SONA: 12.37 (+0.02), BMY: 76.58 (+0.38)
AbbVie Humira Gains FDA Approval for Yet Another Indication
Zacks Equity Research - Zacks Investment Research - Fri Jul 01, 8:04AM CDT
AbbVie's (ABBV) Humira label expanded in the U.S.; the drug can now be used for the treatment of adults with non-infectious intermediate, posterior and panuveitis.
JNJ: 123.00 (+0.08), PFE: 36.31 (+0.07), ABBV: 64.77 (-0.73), BMY: 76.58 (+0.38)
Bayer Expands Drug Discovery Collaboration with X-Chem
Zacks Equity Research - Zacks Investment Research - Wed Jul 13, 3:06PM CDT
Bayer (BAYRY) inked an expanded global drug discovery deal with X-Chem, Inc. across multiple therapeutic areas and target classes.
MACK: 5.36 (-0.33), FCSC: 1.17 (-0.02), BMY: 76.58 (+0.38)
Top 7 Research Reports for July 13, 2016
Sheraz Mian - Zacks Investment Research - Wed Jul 13, 12:00PM CDT
Top 7 Research Reports for July 13, 2016
SU: 28.23 (-0.30), EBAY: 25.12 (-0.01), COP: 42.87 (-0.93), BMY: 76.58 (+0.38), VIAB: 44.80 (-0.64), PEP: 109.91 (+1.12)
Watch for Shares of Bristol-Myers Squibb (BMY) to Approach Resistance at $77.15
Comtex SmarTrend(R) - Wed Jul 13, 8:35AM CDT
Shares of Bristol-Myers Squibb (NYSE:BMY) opened today above their pivot of $76.08 and have already reached the first level of resistance at $76.67. Analysts will be watching for a cross of the next upside pivot targets of $77.15 and $78.22.
BMY: 76.58 (+0.38)
After Yesterday's Rally of 1.31% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Tue Jul 12, 1:52PM CDT
Bristol-Myers Squibb (NYSE:BMY) traded in a range yesterday that spanned from a low of $75.48 to a high of $76.38. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $75.84 on volume of 2.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BMY: 76.58 (+0.38)
Technical Report on Drug Manufacturers - Major Stocks - Bristol-Myers Squibb, AstraZeneca, Eli Lilly, and GlaxoSmithKline
PR Newswire - Mon Jul 11, 6:55AM CDT
On Friday, July 08, 2016, the NASDAQ Composite ended the trading session at 4,956.76, up 1.64%; the Dow Jones Industrial Average advanced 1.40%, to finish at 18,146.74; and the S&P 500 closed at 2,129.90, up 1.53%. The gains were broad based as all the sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Bristol-Myers Squibb Company (NYSE: BMY), AstraZeneca PLC (NYSE: AZN), Eli Lilly and Company (NYSE: LLY), and GlaxoSmithKline PLC (NYSE: GSK). Learn more about these stocks by accessing their free notes at:
AZN: 30.16 (-0.04), LLY: 79.36 (-0.31), GSK: 43.75 (+0.03), BMY: 76.58 (+0.38)
Alnylam (ALNY) Begins Phase I/II Study on Chronic HBV Drug
Zacks Equity Research - Zacks Investment Research - Fri Jul 08, 10:34AM CDT
Alnylam Pharmaceuticals (ALNY) announced that it has started a phase I/II study on ALN-HBV for the treatment of chronic hepatitis B virus infection.
ALNY: 62.82 (-1.18), INVA: 11.89 (+0.13), PFE: 36.31 (+0.07), BMY: 76.58 (+0.38)
Bristol-Myers Buys Cormorant, Focus on Immuno-Oncology
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 9:02AM CDT
Bristol-Myers (BMY) acquires a privately held pharma company, Cormorant Pharmaceuticals, to bolster its immuno-oncology pipeline.
INVA: 11.89 (+0.13), PFE: 36.31 (+0.07), BMY: 76.58 (+0.38)
CSI Laboratories Launches PD-L1 Expression Assay That Can Be Used in Conjunction with Multiple Immunotherapies
BusinessWire - Thu Jul 07, 7:30AM CDT
CSI Laboratories, a private national reference laboratory specializing in cancer diagnostics, announced today the availability of a PD-L1 (programmed death-ligand 1) immunohistochemical (IHC) protein expression assay that can be used to potentially predict a patient's response to several commercially available PD-1/PD-L1 inhibitor therapies.(1)
MRK: 59.55 (-0.05), BMY: 76.58 (+0.38)
Amgen's Kyprolis Gains Approval in EU for Label Expansion
Zacks Equity Research - Zacks Investment Research - Wed Jul 06, 9:37AM CDT
Amgen's (AMGN) Kyprolis label has been expanded in the EU for the treatment of relapsed multiple myeloma patients.
AMGN: 160.52 (-1.44), ABBV: 64.77 (-0.73), BMY: 76.58 (+0.38), CELG: 101.76 (-1.65)
Bristol-Myers Squibb, Deutsche Bank, Alphabet, Blucora and Internap highlighted as Zacks Bull and Bear of the Day
Zacks Equity Research - Zacks Investment Research - Tue Jul 05, 8:30AM CDT
Bristol-Myers Squibb, Deutsche Bank, Alphabet, Blucora and Internap highlighted as Zacks Bull and Bear of the Day
DB: 13.95 (-0.15), GOOGL: 729.48 (-3.03), BMY: 76.58 (+0.38), INAP: 2.42 (+0.04), BCOR: 12.09 (+0.15)
Zacks.com featured highlights: Fresh Del Monte Produce, Post Holdings, Bristol-Myers Squibb, Southern National Bancorp of Virginia and Apple Hospitality REIT
Zacks Equity Research - Zacks Investment Research - Tue Jul 05, 8:30AM CDT
Zacks.com featured highlights: Fresh Del Monte Produce, Post Holdings, Bristol-Myers Squibb, Southern National Bancorp of Virginia and Apple Hospitality REIT
POST: 86.98 (+0.59), APLE: 19.70 (+0.14), FDP: 55.32 (+0.69), SONA: 12.37 (+0.02), BMY: 76.58 (+0.38)
Bristol-Myers Squibb Acquires Cormorant Pharmaceuticals
BusinessWire - Tue Jul 05, 5:59AM CDT
--Broadens Bristol-Myers Squibb's oncology pipeline focus on the tumor microenvironment and combination therapy
BMY: 76.58 (+0.38)
Bull of the Day: Bristol-Myers Squibb (BMY)
Neena Mishra - ZACKS - Tue Jul 05, 2:40AM CDT
Bull of the Day: Bristol-Myers Squibb (BMY)
BMY: 76.58 (+0.38)
XBiotech Xilonix Positive in Phase III Colorectal Cancer Study
Zacks Equity Research - Zacks Investment Research - Mon Jul 04, 8:06AM CDT
XBiotech (XBIT) announced positive results from a phase III study on Xilonix for the treatment of advanced colorectal cancer.
XBIT: 18.21 (-0.03), ANIP: 54.26 (-1.47), PFE: 36.31 (+0.07), BMY: 76.58 (+0.38)
Novartis' Systemic Mastocytosis Drug Positive in Phase II
Zacks Equity Research - Zacks Investment Research - Fri Jul 01, 3:43PM CDT
Novartis AG (NVS) announced that data from its phase II study, CPKC412D2201, on PKC412 (midostaurin) was published in The New England Journal of Medicine.
JNJ: 123.00 (+0.08), PFE: 36.31 (+0.07), BMY: 76.58 (+0.38), NVS: 82.03 (+0.35)
Shire Stock Up Despite Mixed Data on Pipeline Candidate
Zacks Equity Research - Zacks Investment Research - Fri Jul 01, 3:30PM CDT
Shire plc (SHPG) announced disappointing results from a phase II study on pipeline candidate SHP607.
JNJ: 123.00 (+0.08), SHPG: 192.49 (-2.82), PFE: 36.31 (+0.07), BMY: 76.58 (+0.38)
5 Low Beta Stocks to Withstand Market Volatility
Zacks Equity Research - Zacks Investment Research - Fri Jul 01, 8:46AM CDT
It will be wise if investors include low risk stocks in their portfolio. Such a portfolio could be created easily based on the low beta strategy which selects stocks less prone to risks than the market.
POST: 86.98 (+0.59), APLE: 19.70 (+0.14), FDP: 55.32 (+0.69), SONA: 12.37 (+0.02), BMY: 76.58 (+0.38)
AbbVie Humira Gains FDA Approval for Yet Another Indication
Zacks Equity Research - Zacks Investment Research - Fri Jul 01, 8:04AM CDT
AbbVie's (ABBV) Humira label expanded in the U.S.; the drug can now be used for the treatment of adults with non-infectious intermediate, posterior and panuveitis.
JNJ: 123.00 (+0.08), PFE: 36.31 (+0.07), ABBV: 64.77 (-0.73), BMY: 76.58 (+0.38)
